Education Alert
Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
0.50 CME / CE / ABIM MOC
Did you know that approximately 50% of breast cancer patients who have been exposed to an AI over time in the metastatic setting develop an ESR1 mutation?